8 Administration of miglustat to male and female CD1 mice by oral gavage at dose levels of 210, 420 and 840/ 500 mg/ kg/ day (dose reduction after half a year) for 2 years resulted in an increased incidence of inflammatory and hyperplastic lesions in the large intestine in both sexes.